- Home
- BPMC vs JHG Comparison
BPMC vs JHG Comparison
Compare BPMC & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- JHG
- Stock Information
- Founded
- BPMC 2008
- JHG 1934
- Country
- BPMC United States
- JHG United Kingdom
- Employees
- BPMC N/A
- JHG N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- JHG Investment Managers
- Sector
- BPMC Health Care
- JHG Finance
- Exchange
- BPMC Nasdaq
- JHG Nasdaq
- Market Cap
- BPMC 5.8B
- JHG 5.8B
- IPO Year
- BPMC 2015
- JHG N/A
- Fundamental
- Price
- BPMC $84.69
- JHG $30.72
- Analyst Decision
- BPMC Buy
- JHG Buy
- Analyst Count
- BPMC 22
- JHG 12
- Target Price
- BPMC $124.48
- JHG $41.83
- AVG Volume (30 Days)
- BPMC 1.2M
- JHG 1.8M
- Earning Date
- BPMC 05-01-2025
- JHG 05-01-2025
- Dividend Yield
- BPMC N/A
- JHG 5.08%
- EPS Growth
- BPMC N/A
- JHG 8.02
- EPS
- BPMC N/A
- JHG 2.56
- Revenue
- BPMC $508,824,000.00
- JHG $2,473,200,000.00
- Revenue This Year
- BPMC $45.70
- JHG $2.62
- Revenue Next Year
- BPMC $31.83
- JHG $6.26
- P/E Ratio
- BPMC N/A
- JHG $12.00
- Revenue Growth
- BPMC 104.04
- JHG 17.67
- 52 Week Low
- BPMC $73.04
- JHG $28.26
- 52 Week High
- BPMC $121.90
- JHG $46.68
- Technical
- Relative Strength Index (RSI)
- BPMC 47.15
- JHG 35.77
- Support Level
- BPMC $78.66
- JHG $30.10
- Resistance Level
- BPMC $83.50
- JHG $31.89
- Average True Range (ATR)
- BPMC 5.00
- JHG 1.82
- MACD
- BPMC 0.20
- JHG -0.03
- Stochastic Oscillator
- BPMC 67.15
- JHG 28.31
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.